Product news from the 10/21/05 News Brief

Share this article:

The FDA approved the expanded use of GlaxoSmithKline's Havrix (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix.

Esprit Pharma acquired exclusive North American rights to Estrasorb (estradiol topical emulsion) from Novavax. A topical emulsion form of the naturally occurring hormone beta-estradiol 17, Estrasorb is the first prescription topical emulsion for estrogen therapy.

Upsher-Smith Laboratories introduced new Vandazole (metronidazole vaginal gel, 0.75 percent) for treatment of bacterial vaginosis in non-pregnant patients.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies